• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed

    2/16/21 3:28:16 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VYNE alert in real time by email
    SC 13G/A 1 b021221a.htm SCHEDULE 13G (AMENDMENT #1)
    240.13d-102 Schedule 13G - Information to be included in statements filed
    pursuant to 240.13d-1(b), (c), and (d) and amendments thereto
    filed pursuant to 240.13d-2.
    Securities and Exchange Commission, Washington, D.C. 20549
    Schedule 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    (Name of Issuer)
    Vyne Therapeutics Inc. (formerly known as Menlo Therapeutics Inc.)
    (Title of Class of Securities)
    Common Stock, Par Value $0.0001 Per Share

    (CUSIP Number)

    92941V100
    (Date of Event Which Requires Filing of this Statement)
    December 31, 2020
    Check the appropriate box to designate the rule pursuant to which this
    Schedule is filed:
    [  ] Rule 13d-1(b)
    [ x ] Rule 13d-1(c)
    [  ] Rule 13d-1(d)
    *The remainder of this cover page shall be filled out for a reporting person's
    initial filing on this form with respect to the subject class of securities, and
    for any subsequent amendment containing information which would alter the
    disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be
    deemed to be “filed” for the purpose of Section 18 of the Securities Exchange
    Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the
    Act but shall be subject to all other provisions of the Act (however, see
    the Notes).




    CUSIP No. 92941V100
    (1) Names of reporting persons    Point72 Asset Management, L.P.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              0 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       0 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    0 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0% (see Item 4)
     
    (12) Type of reporting person (see instructions)     PN
     


    CUSIP No. 92941V100
    (1) Names of reporting persons    Point72 Capital Advisors, Inc.
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              0 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       0 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    0 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) 0% (see Item 4)
     
    (12) Type of reporting person (see instructions)  CO
     


    CUSIP No. 92941V100
    (1) Names of reporting persons    Cubist Systematic Strategies, LLC
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Delaware
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              25,500 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       25,500 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    25,500 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1% (see Item 4)
     
    (12) Type of reporting person (see instructions)  OO
     


    CUSIP No. 92941V100
    (1) Names of reporting persons    Point72 Hong Kong Limited
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization Hong Kong
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              540 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       540 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    540 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1% (see Item 4)
     
    (12) Type of reporting person (see instructions)     OO
     


    CUSIP No. 92941V100
    (1) Names of reporting persons    Steven A. Cohen
     
    (2) Check the appropriate box if a member of a group
    (a)
    (see instructions)
    (b)X
    (3) SEC use only
     
    (4) Citizenship or place of organization United States
     
    Number of shares beneficially owned by each reporting person with:
     
    (5) Sole voting power                  0
     
    (6) Shared voting power              26,040 (see Item 4)
     
    (7) Sole dispositive power           0
     
    (8) Shared dispositive power       26,040 (see Item 4)
     
    (9) Aggregate amount beneficially owned by each reporting person
    26,040 (see Item 4)
     
    (10) Check if the aggregate amount in Row (9) excludes certain shares
    (see instructions)
     
    (11) Percent of class represented by amount in Row (9) <0.1% (see Item 4)
     
    (12) Type of reporting person (see instructions) IN
     


    Item 1(a) Name of issuer:
    Vyne Therapeutics Inc.
    Item 1(b) Address of issuer's principal executive offices:
    520 U.S. Highway 22, Suite 204, Bridgewater, New Jersey 08807
    2(a) Name of person filing:
    This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset
    Management”) with respect to shares of common stock, par value $0.0001 per share
    (“Shares”), of the Issuer held by certain investment funds it manages; (ii)
    Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect
    to Shares held by certain investment funds managed by Point72 Asset
    Management; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic
    Strategies”) with respect to Shares held by certain investment funds it
    manages; (iv) Point72 Hong Kong Limited (“Point72 Hong Kong”) with respect to
    Shares held by certain investment funds it manages; and (v) Steven A. Cohen
    (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset
    Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and
    Point72 Hong Kong.
    2(b) Address or principal business office or, if none, residence:
    The address of the principal business office of (i) Point72 Asset Management,
    Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road,
    Stamford, CT 06902; (ii) Cubist Systematic Strategies is 55 Hudson Yards,
    New York, NY 10001; and (iii) Point72 Hong Kong is 12th Floor, Chater House, 8
    Connaught Road Central, Hong Kong.
    2(c) Citizenship:
    Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a
    Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company.
    Point72 Hong Kong is a Hong Kong limited liability company. Mr. Cohen is a United States
    citizen.
    2(d) Title of class of securities:
    Common Stock, Par Value $0.0001 Per Share
    2(e) CUSIP Number:
    92941V100

    Item 3.

    Not applicable

    Item 4. Ownership

    As of the close of business on December 31, 2020:

    1. Point72 Asset Management, L.P.
    (a) Amount beneficially owned: 0
    (b) Percent of class: 0% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 0 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 0

    2. Point72 Capital Advisors, Inc.
    (a) Amount beneficially owned: 0
    (b) Percent of class: 0% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 0 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 0

    3. Cubist Systematic Strategies, LLC
    (a) Amount beneficially owned: 25,500
    (b) Percent of class: <0.1% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 25,500 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 25,500

    4. Point72 Hong Kong Limited
    (a) Amount beneficially owned: 540
    (b) Percent of class: <0.1% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 540 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 540

    5. Steven A. Cohen
    (a) Amount beneficially owned: 26,040
    (b) Percent of class: <0.1% 
    (c) Number of shares as to which the person has:
    (i) Sole power to vote or to direct the vote: 0
    (ii) Shared power to vote or to direct the vote: 26,040 
    (iii) Sole power to dispose or to direct the disposition of: 0
    (iv) Shared power to dispose or to direct the disposition of: 26,040
    Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic
    Strategies, Point72 Hong Kong, and Mr. Cohen own directly no Shares. Pursuant
    to an investment management agreement, Point72 Asset Management maintains
    investment and voting power with respect to the securities held by certain
    investment funds it manages. Point72 Capital Advisors Inc. is the general
    partner of Point72 Asset Management. Pursuant to an investment management
    agreement, Cubist Systematic Strategies maintains investment and voting power
    with respect to the securities held by certain investment funds it manages.
    Pursuant to an investment management agreement, Point72 Hong Kong maintains
    investment and voting power with respect to the securities held by certain investment funds it
    manages. Mr. Cohen controls each of Point72 Asset Management, Point72 Capital Advisors Inc.,
    Cubist Systematic Strategies, and Point72 Hong Kong.  As of December 31, 2020, by reason of
    the provisions of Rule 13d-3 of the Securities Exchange Act of 1934, as amended, each of (i)
    Cubist Systematic Strategies and Mr. Cohen may be deemed to beneficially own 25,500 Shares
    (constituting <0.1% of the Shares outstanding) and (ii) Point72 Hong Kong and Mr. Cohen may
    be deemed to beneficially own 540 Shares (constituting <0.1% of the Shares outstanding).   Each
    of Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies,
    Point72 Hong Kong, and Mr. Cohen disclaims beneficial ownership of any of the securities
    covered by this statement.
    Item 5.  Ownership of 5 Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof
    the reporting person has ceased to be the beneficial owner of more than
    5 percent of the class of securities, check the following [X].

    Item 6.  Ownership of More than 5 Percent on Behalf of Another Person.

    Not applicable

    Item 7.  Identification and Classification of the Subsidiary Which Acquired
    the Security Being Reporting on by the Parent Holding Company or Control
    Person.
    Not applicable
    Item 8. Identification and Classification of Members of the Group

    Not applicable

    Item 9.  Notice of Dissolution of Group.

    Not applicable

    Item 10. Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to
    above were not acquired and are not held for the purpose of or with the effect of changing or
    influencing the control of the issuer of the securities and were not acquired and are not held in
    connection with or as a participant in any transaction having that purpose or effect, other than
    activities solely in connection with a nomination under§ 240.14a-11.

    Signature.  After reasonable inquiry and to the best of my knowledge and belief,
    I certify that the information set forth in this statement is true, complete
    and correct.

    Dated: February 16, 2021

    POINT72 ASSET MANAGEMENT, L.P.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    POINT72 CAPITAL ADVISORS, INC.
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    CUBIST SYSTEMATIC STRATEGIES, LLC
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    POINT72 HONG KONG LIMITED
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person

    STEVEN A. COHEN
    By: /s/ Jason M. Colombo
    Name: Jason M. Colombo
    Title: Authorized Person


    Get the next $VYNE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VYNE

    DatePrice TargetRatingAnalyst
    7/31/2025Buy → Neutral
    BTIG Research
    11/18/2024$8.00Buy
    BTIG Research
    12/6/2021$7.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $VYNE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

    Following closing, combined company plans to progress Yarrow's lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor ("TSHR") antibody for Graves' disease ("GD") and thyroid eye disease ("TED")Yarrow Bioscience is the seventh biotechnology company founded by RTW Investments and plans to advance in-licensed asset YB-101 (also known as GS-098) into a U.S.-based Phase 1b/2b trial in patients with GD in the first half of 2026; a Phase 1 trial in TED is being conducted in China by partner Changchun GeneScience Pharmaceutical Co., Ltd ("GenSci")Pre-closing private financings totaling approximately $200 million expected to fund operations into 2028Companies to

    12/17/25 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update

    Company is progressing its previously initiated strategic review evaluating a range of options to maximize shareholder value, including assessment of internal pipeline opportunities and broader strategic alternatives12-week, non-clinical toxicology study of VYN202 in dogs to remedy the partial hold in male clinical subjects is ongoing; Company continues to evaluate potential opportunities for VYN202 as a treatment for serious, immune-mediated diseases Cash runway into first half of 2027 based on previously announced cost reductions BRIDGEWATER, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company

    11/6/25 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

    BRIDGEWATER, N.J., Aug. 14, 2025 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company focused on developing differentiated therapies to treat chronic inflammatory and immune-mediated conditions with high unmet need, today reported financial results as of and for the quarter ended June 30, 2025. The Company is actively evaluating opportunities to enhance the value of its pipeline programs. VYNE's oral BD2-selective BET inhibitor, VYN202, has recently demonstrated a promising efficacy signal in a Phase 1b clinical trial in moderate to severe plaque psoriasis, as well as disease-modifying potential across multiple tran

    8/14/25 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    SEC Filings

    View All

    SEC Form 425 filed by VYNE Therapeutics Inc.

    425 - VYNE Therapeutics Inc. (0001566044) (Subject)

    1/30/26 4:11:47 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

    8-K - VYNE Therapeutics Inc. (0001566044) (Filer)

    1/30/26 4:10:56 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 425 filed by VYNE Therapeutics Inc.

    425 - VYNE Therapeutics Inc. (0001566044) (Subject)

    12/17/25 8:16:49 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lepore Patrick G bought $43,800 worth of shares (15,000 units at $2.92), increasing direct ownership by 41% to 51,472 units (SEC Form 4)

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    1/16/25 6:06:19 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lepore Patrick G bought $50,778 worth of shares (13,000 units at $3.91), increasing direct ownership by 55% to 36,472 units (SEC Form 4)

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    11/17/23 5:03:12 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT AND CEO Domzalski David covered exercise/tax liability with 12,684 shares, decreasing direct ownership by 3% to 416,208 units (SEC Form 4)

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    1/5/26 8:30:40 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF SCIENTIFIC OFFICER Stuart Iain covered exercise/tax liability with 2,448 shares, decreasing direct ownership by 2% to 115,239 units (SEC Form 4)

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    1/5/26 8:30:07 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CHIEF FINANCIAL OFFICER Zeronda Tyler covered exercise/tax liability with 7,858 shares, decreasing direct ownership by 7% to 103,795 units (SEC Form 4)

    4 - VYNE Therapeutics Inc. (0001566044) (Issuer)

    1/5/26 8:30:09 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    VYNE Therapeutics downgraded by BTIG Research

    BTIG Research downgraded VYNE Therapeutics from Buy to Neutral

    7/31/25 7:17:36 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BTIG Research initiated coverage on VYNE Therapeutics with a new price target

    BTIG Research initiated coverage of VYNE Therapeutics with a rating of Buy and set a new price target of $8.00

    11/18/24 7:58:59 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    HC Wainwright & Co. resumed coverage on VYNE Therapeutics with a new price target

    HC Wainwright & Co. resumed coverage of VYNE Therapeutics with a rating of Buy and set a new price target of $7.00

    12/6/21 6:30:12 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    Leadership Updates

    Live Leadership Updates

    View All

    VYNE Therapeutics Announces Appointment of Subhashis Banerjee, M.D. as Senior Vice President of Clinical Development

    BRIDGEWATER, N.J., July 09, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the appointment of Subhashis Banerjee, M.D., as Senior Vice President of Clinical Development, effective as of July 8, 2024. Dr. Banerjee is a trained immunologist and rheumatologist with over 25 years of drug development experience at large pharmaceutical companies, including with the development of therapies for psoriasis and arthritic conditions. "We are pleased to welcome Dr. Banerjee to the VYNE

    7/9/24 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics Appoints Christine Borowski, Ph.D., to its Board of Directors

    BRIDGEWATER, N.J., Jan. 03, 2024 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a clinical-stage biopharmaceutical company developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced the appointment of Christine Borowski, Ph.D., to its board of directors, effective as of January 1, 2024. "We are pleased to welcome Dr. Borowski to our Board of Directors during this important time in the Company's growth," said David Domzalski, President and CEO of VYNE. "With her expertise in immunology and extensive experience in the biopharmaceutical industry, Dr. Borowski will provide valuable p

    1/3/24 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    Financials

    Live finance-specific insights

    View All

    VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement

    Following closing, combined company plans to progress Yarrow's lead program, YB-101, a potentially first-in-class anti-thyroid-stimulating hormone receptor ("TSHR") antibody for Graves' disease ("GD") and thyroid eye disease ("TED")Yarrow Bioscience is the seventh biotechnology company founded by RTW Investments and plans to advance in-licensed asset YB-101 (also known as GS-098) into a U.S.-based Phase 1b/2b trial in patients with GD in the first half of 2026; a Phase 1 trial in TED is being conducted in China by partner Changchun GeneScience Pharmaceutical Co., Ltd ("GenSci")Pre-closing private financings totaling approximately $200 million expected to fund operations into 2028Companies to

    12/17/25 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics Announces Reverse Stock Split

    BRIDGEWATER, N.J., Feb. 10, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company"), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced that its Board of Directors has approved a reverse stock split of the Company's common stock at a ratio of 1-for-18. The reverse stock split was previously approved by stockholders at the Special Meeting of Stockholders on January 12, 2023. The reverse stock split will become effective after market close on Friday, February 10, 2023 and shares will begin trading on a split-adjusted basis when the market opens on Mo

    2/10/23 8:00:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    VYNE Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update

    Lead BET Inhibitor Candidate, VYN201, Demonstrates Potent Anti-Inflammatory Effect in Preclinical Studies VYN201 Expected to Enter Clinic in 2022 Phase 2a Results for FMX114 in Mild-to-Moderate Atopic Dermatitis Expected Early Q1 2022 Process for Sale of Topical Minocycline Franchise Continues to Advance Conference call and Live Webcast Today at 8:30 am Eastern Time BRIDGEWATER, N.J., Nov. 10, 2021 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (NASDAQ:VYNE) ("VYNE" or the "Company") today announced financial results for the third quarter ended September 30, 2021 and provided a business update. "The third quarter marks an important turning point for VYNE, as our company is now fully enga

    11/10/21 7:30:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $VYNE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by VYNE Therapeutics Inc.

    SC 13G/A - VYNE Therapeutics Inc. (0001566044) (Subject)

    11/14/24 3:34:53 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by VYNE Therapeutics Inc. (Amendment)

    SC 13G/A - VYNE Therapeutics Inc. (0001566044) (Subject)

    2/14/24 4:57:08 PM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by VYNE Therapeutics Inc. (Amendment)

    SC 13G/A - VYNE Therapeutics Inc. (0001566044) (Subject)

    2/2/24 9:42:00 AM ET
    $VYNE
    Biotechnology: Pharmaceutical Preparations
    Health Care